1. Home
  2. QSI vs ALLO Comparison

QSI vs ALLO Comparison

Compare QSI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum-Si Incorporated

QSI

Quantum-Si Incorporated

HOLD

Current Price

$1.25

Market Cap

273.7M

Sector

Health Care

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.56

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QSI
ALLO
Founded
2013
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
273.7M
252.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
QSI
ALLO
Price
$1.25
$1.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
12
Target Price
$2.63
$8.27
AVG Volume (30 Days)
5.4M
5.0M
Earning Date
03-02-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,177,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$159.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40.20
N/A
52 Week Low
$0.95
$0.86
52 Week High
$3.10
$3.78

Technical Indicators

Market Signals
Indicator
QSI
ALLO
Relative Strength Index (RSI) 48.00 50.75
Support Level $1.14 $1.46
Resistance Level $1.33 $1.83
Average True Range (ATR) 0.08 0.13
MACD 0.01 -0.01
Stochastic Oscillator 52.63 25.56

Price Performance

Historical Comparison
QSI
ALLO

About QSI Quantum-Si Incorporated

Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: